Kenvue Inc. Stock Price, News & Analysis

Kenvue Inc. (NYSE: KVUE) reported its Q2 2024 financial results, showing net sales of $4.0 billion, a 0.3% decrease year-over-year, with organic growth of 1.5%. The company's diluted EPS was $0.03, while adjusted diluted EPS reached $0.32. Kenvue's gross profit margin expanded by 360 basis points to 59.1%, and adjusted gross profit margin increased by 410 basis points to 61.6%. The company took a non-cash charge of $488 million related to the Dr.Ci:Labo® business impairment. Despite challenges, Kenvue reaffirmed its 2024 outlook, projecting net sales growth of 1.0%-3.0% and adjusted diluted EPS between $1.10-$1.20.

Kenvue Inc. (NYSE: KVUE), the world's largest pure-play consumer health company, has announced changes to its Board of Directors. Kathleen M. Pawlus and Kirk L. Perry will join as new independent directors, effective August 15, 2024, and December 1, 2024, respectively. Pawlus, with over 40 years of experience in finance and operations, will serve on the Audit Committee. Perry, currently President and CEO of Circana, brings extensive consumer packaged goods and technology experience and will join the Compensation & Human Capital Committee.

Concurrently, Peter M. Fasolo and Joseph J. Wolk, current Johnson & Johnson executives, will resign from the Board in December 2024. This succession process aligns with Kenvue's commitment to independent Board oversight and follows Johnson & Johnson's divestment of its remaining stake in Kenvue in May 2024. By the 2025 Annual Meeting, Kenvue expects its Board to comprise 11 directors, with 10 being independent.

Kenvue Inc. (NYSE: KVUE), the world's largest pure-play consumer health company by revenue, has announced a 2.5% increase in its quarterly dividend. The company's Board of Directors declared a $0.205 per share dividend on Kenvue common stock for the third quarter of 2024. This increase demonstrates Kenvue's commitment to returning cash to shareholders as part of its capital allocation strategy aimed at enabling sustainable growth and optimizing total shareholder return.

The dividend will be payable on August 28, 2024, to shareholders of record as of the close of business on August 14, 2024. Kenvue's portfolio includes iconic brands such as Aveeno®, BAND-AID®, Johnson's®, Listerine®, Neutrogena®, and Tylenol®, which are science-backed and recommended by healthcare professionals worldwide.

Kenvue (NYSE: KVUE), the leading global consumer health company, will release its second-quarter 2024 financial results on August 6, 2024, before the market opens. The results will cover the quarter ending June 30, 2024.

A conference call and webcast will follow at 8:30 a.m. Eastern Time to discuss the results. U.S. participants can dial 877-407-8835, while international participants can dial +1 201-689-8779 to join the call. The webcast will be available on Kenvue's investor relations website, with a replay accessible post-event.

Kenvue, known for brands like Aveeno, BAND-AID, Johnson’s, Listerine, Neutrogena, and Tylenol, emphasizes the importance of everyday care, with products supported by scientific research and healthcare professionals globally.

Kenvue, the world's largest pure-play consumer health company by revenue, has released its first Healthy Lives Mission Report. The report highlights significant progress in Environmental, Social, and Governance (ESG) goals since becoming an independent company. Key achievements include a 26% reduction in Scope 1 and 2 GHG emissions since 2020, increased use of renewable electricity to 65%, and 71% of their packaging being recyclable or refillable. The company also reports gender parity in its global workforce and a commitment to diversity, with 36% of U.S. employees identifying as racial or ethnic minorities. Kenvue continues to develop inclusive products and promote sustainable practices, aiming for long-term positive impacts on people and the planet.

Kenvue (NYSE: KVUE) announced its participation in Deutsche Bank's dbAccess Global Consumer Conference in Paris, France. Key executives, including CEO Thibaut Mongon, CFO Paul Ruh, and Group President Carlton Lawson, will engage in a fireside chat on June 4, 2024, at 8:45 a.m. Eastern Time / 2:45 p.m. Central European Time. The session will be webcast live on Kenvue's investor relations website, with a replay available afterward. Kenvue, a leading pure-play consumer health company with renowned brands such as Aveeno, BAND-AID, Johnson’s, Listerine, Neutrogena, and Tylenol, is committed to leveraging everyday care for consumer well-being.

Kenvue (NYSE: KVUE) announced the pricing of its secondary underwritten public offering of 182,329,550 shares of common stock at $20.00 per share, expected to close on May 17, 2024.

Kenvue will not sell any shares or receive proceeds from the offering. Instead, Johnson & Johnson (NYSE: JNJ) is expected to exchange these shares for its indebtedness held by Goldman Sachs & Co. and J.P. Morgan, who will then sell the shares to underwriters.

Post-offering, Johnson & Johnson will no longer own any shares of Kenvue. The offering will be managed by Goldman Sachs, J.P. Morgan, BofA Securities, and others. A registration statement on Form S-1 has been filed and declared effective by the SEC.

Kenvue Inc. (NYSE: KVUE) has announced the launch of a secondary underwritten public offering of 182,329,550 shares of its common stock. The offering involves the exchange of shares between Kenvue and Johnson & Johnson, with Goldman Sachs & Co. and J.P. Morgan acting as selling shareholders. Following the exchange, the selling shareholders will sell the shares to underwriters. Johnson & Johnson will no longer own any shares of Kenvue's common stock after the completion of the offering.

Kenvue Inc. (NYSE: KVUE) reported first quarter 2024 results with a 1.1% increase in net sales to $3.9 billion and 1.9% organic growth. Diluted earnings per share were $0.15, adjusted to $0.28. Gross profit margin expanded to 57.6%, operating income margin was 14.1%. Initiatives were approved to reduce the global workforce by 4% with cost savings of $350 million by 2026. Outlook for 2024 includes a reported net sales growth of 1.0% to 3.0% and adjusted diluted earnings per share in the range of $1.10 - $1.20.